AV Troitsky¹*, TN Bystrova¹, AA Rozhkov ², NA Mamontov² and KA Rozhkova²

¹Federal Research Center for Fundamental and Translational Medicine, Novosibirsk, Russia
²Innovative Health Technologies LLC, Novosibirsk, Russia

*Corresponding Author: AV Troitsky, Federal Research Center for Fundamental and Translational Medicine, Novosibirsk, Russia.

Received: August 22, 2024; Published: September 11, 2024

Abstract

The gastroprotective effect of low molecular weight chitosan was studied on a model of indomethacin gastropathy in Wistar rats. An assessment of the areas of ribbon and point erosions in the gastric mucosa in rats after intragastric administration of indomethacin suspension at a dose of 60 mg per 1 kg of body weight showed that intragastric administration of 0.2% aqueous solution of low molecular weight chitosan (50 kDa) 1 hour after administration of indomethacin significantly reduces the areas of erosion in the gastric mucosa. This effect is especially pronounced in the analysis of band erosions, as the most severe form of nonsteroidal gastropathy. The data obtained may be of significant interest for the creation of combined dosage forms of NSAIDs with minimal damaging effect on the gastric mucosa.

 Keywords: Nonsteroidal Gastropathy; Chitosan; Indomethacin Gastropathy

References

1. Tsimmerman YaS. “Gastroduodenal lesion induced by non-steroidal anti-inflammatory drugs (NSAIDs): NSAID-gastritis or NSAID-gastropathy?” Clinical Pharmacology Therapy1 (2018): 14-21.
2. “Preventive and therapeutic strategies of pharmaco-correction gastropathy induced by nonsteroidal anti-inflammatory drugs”. Reviews on Clinical Pharmacology and Drug Therapy4 (2017): 14-23.
3. Takeuchi K. “Pathogenesis of NSAID-induced gastric damage: Importance of cyclooxygenase inhibition and gastric hypermotility”. World Journal of Gastroenterology18 (2012): 2147-2160.
4. Lamarque D. “Physiopathologie des lésions gastro-duodénales induites par les anti-inflammatoires non stéroïdiens [Pathogenesis of gastroduodenal lesions induced by non-steroidal anti-inflammatory drugs]”. Gastroentérologie Clinique et Biologique 3 (2004): C18-26.
5. Lanas A. “Cyclo-oxygenase-1/cyclo-oxygenase-2 non-selective non-steroidal anti-inflammatory drugs: epidemiology of gastrointestinal events”. Digestive and Liver Disease 2 (2001): S29-34.
6. Viktorova IA., et al. “Modern possibilities for the treatment and prevention of NSAID-induced enteropathies”. Medical Advice 5 (2020): 30–40.
7. Zharikov AYu., et al. “Search for new oligopeptide molecules for pharmacological correction of NSAID-induced gastric ulcers”. Biomedicine3 (2019): 90-97.
8. Gmurov DV., et al. “NSAIDS-associated peptic ulcer of the stomach and duodenum”. Technical Science Colloquium-journal63 (2020).
9. Chinese Rheumatism Data Center; Chinese Systemic Lupus Erythematosus Treatment and Research Group. “[Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications]”. Zhonghua Nei Ke Za Zhi1 (2017): 81-85.
10. Adefisayo MA., et al. “Gastro-protective effect of methanol extract of Vernonia amygdalina (del.) leaf on aspirin-induced gastric ulcer in Wistar rats”. Toxicology Report 4 (2017): 625-633.
11. Hladkykh FV. “Preventive and therapeutic strategies of pharmaco-correction gastropathy induced by nonsteroidal anti-inflammatory drugs”. Reviews on Clinical Pharmacology and Drug Therapy4 (2017): 14-23.
12. Singh G. “Recent considerations in nonsteroidal anti-inflammatory drug gastropathy”. The American Journal of Medicine 1B (1998): 31S-38S.

Citation

Citation: AV Troitsky., et al. “Study of the Cytoprotective Effect of Low Molecular Weight Chitosan on a Model of Indomethacin Gastropathy in Rats”.Acta Scientific Medical Sciences 8.10 (2024): 48-52.

Copyright

Copyright: © 2024 AV Troitsky., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.